OrganoClick R&D per Employee
The R&D Spending per Employee of OrganoClick (ORGC.ST) as of Oct 11, 2026 is 29,882.35 SEK. In the previous year, R&D Spending per Employee was 116,352.94 SEK — a change of -74.32% (lower).
Get this data via API
Financial Data API
R&D per Employee
29,882.35SEK
YoY
-74.32%
Last updated:
The OrganoClick R&D per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | R&D per Employee | YoY |
|---|---|---|
| 29,882.35SEK | -74.32% | |
| 116,352.94SEK | -10.78% | |
| 130,411.76SEK | -45.49% | |
| 239,254.90SEK | +62.63% | |
| 147,117.65SEK | +37.64% | |
| 106,882.35SEK | +26.92% | |
| 84,215.69SEK | +27.30% | |
| 66,156.86SEK | -2.74% | |
| 68,019.61SEK | +4.46% | |
| 65,117.65SEK | -9.85% | |
| 72,235.29SEK | -38.13% | |
| 116,745.10SEK | — |
OrganoClick Stock analysis
Frequently Asked Questions about OrganoClick stock
R&D Spending per Employee of OrganoClick is 29,882.35 SEK in 2025.
R&D Spending per Employee of OrganoClick changed from 116,352.94 SEK to 29,882.35 SEK, representing a -74.32% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of R&D Spending per Employee OrganoClick since 2006 – with annual values, charts, and detailed analysis.
R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.
R&D Spending per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's OrganoClick historically and in real time.
Workforce — OrganoClick
All Key Metrics — OrganoClick
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth